Tonix Pharmaceuticals Holding Co (TNXP) announced that it expects to launch a Phase 2 clinical trial of its candidate drug Tonmya for the treatment of major depressive disorder (MDD) in the middle of this year.

This development marks an important step forward for the company in expanding its core product pipeline. Major depressive disorder is a common and severe mental health disorder that affects millions of people worldwide, and there remains a significant unmet clinical need. As a novel potential therapy, Tonmya’s phase II study aims to evaluate the efficacy and safety of this drug in patients with MDD. The company plans to initiate this study around mid-year, with the specific timeline dependent on regulatory feedback and final preparations. The anticipated initiation of this study reflects Tonix Pharmaceuticals’ ongoing efforts to advance the development of its therapies for neuropsychiatric disorders. The market will closely monitor further progress of this study and its potential clinical value.